Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696647 | 0.93 | CLPP (0.35) | MAPK1GRM4 | |
| SCHEMBL6702121 | 0.91 | ABCB1 (0.34) | MAPK1ALDH1A1POLB | |
| SCHEMBL6698925 | 0.81 | MAPK1 (0.35) | MAPK1SCD | |
| SCHEMBL6700329 | 0.76 | ALDH1A1 (0.35) | MAPK1ALDH1A1HTT | |
| SCHEMBL6814225 | 0.76 | P2RX7 (0.35) | MAPK1SCDALDH1A1HTT | |
| SCHEMBL6706967 | 0.74 | MMP13 (0.38) | — | |
| SCHEMBL6700135 | 0.74 | MAPK1 (0.35) | MAPK1SCD | |
| SCHEMBL6700606 | 0.74 | CLPP (0.38) | MAPK1SCDALDH1A1POLB | |
| SCHEMBL6699940 | 0.73 | MAPK1 (0.34) | MAPK1ALDH1A1POLB | |
| SCHEMBL6704262 | 0.72 | P2RX7 (0.36) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPK1 1571/4885SCD 2142/4885GRM4 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.